Jay Cutler TRT: What the Bodybuilding Champion Has Said About Testosterone Replacement Therapy

What Jay Cutler Has Actually Said About TRT

Jay Cutler has not hidden his TRT use. Across several podcast appearances, including episodes of the Generation Iron podcast network and conversations with fellow competitors, he has described testosterone replacement as a medical necessity following his retirement from the IFBB Pro stage. He has drawn a direct line between his years of competitive bodybuilding and his current hormonal needs.

In one widely cited exchange, Cutler described his approach plainly: he uses testosterone to maintain normal physiological levels, not to replicate the supraphysiologic doses used during competition prep. He has framed TRT as routine medical maintenance, comparable to how a person with hypothyroidism takes levothyroxine.

Direct Statements From Interviews

Cutler has told interviewers that his testosterone is managed by a physician and that he undergoes regular bloodwork. He has specified that the goal is to keep his levels within a normal adult male reference range, not to exceed it. This is consistent with the clinical definition of TRT as therapy aimed at restoring eugonadal status rather than achieving supraphysiologic concentrations [1].

He has also acknowledged that discontinuing all exogenous androgens after a multi-decade career would leave him with testosterone levels characteristic of severe hypogonadism. That acknowledgment tracks with clinical data: a 2020 study published in the Journal of Clinical Endocrinology and Metabolism found that former anabolic-androgenic steroid (AAS) users had significantly lower LH, FSH, and testosterone concentrations compared with age-matched controls even years after stopping AAS use [2].

What He Has Not Said

Cutler has not publicly disclosed a specific product name, injection frequency, or blood-level target. Any figure circulated on social media claiming to represent his exact protocol is speculative. This article labels those gaps clearly: the clinical framework below is drawn from published guidelines, not from Cutler's personal disclosures.

The Medical Condition Behind His TRT: Post-AAS Hypogonadism

Post-anabolic-androgenic steroid hypogonadism (PASH) is the endocrine state that most commonly drives TRT use among retired professional bodybuilders. The hypothalamic-pituitary-gonadal (HPG) axis operates on negative feedback: when exogenous testosterone or its derivatives are present at high concentrations, the hypothalamus reduces GnRH secretion, and the pituitary reduces LH and FSH output. The testes, receiving little or no gonadotropin signal, shrink and stop producing endogenous testosterone.

How Long Does Suppression Last?

Recovery of the HPG axis after AAS cessation is highly variable. A 2021 systematic review in the British Journal of Sports Medicine found that gonadotropin and testosterone levels may remain subnormal for 12 to 24 months after stopping AAS, and in some individuals suppression is permanent [3]. Duration of prior AAS use, total cumulative dose, and individual genetic variation in the androgen receptor all appear to influence recovery potential.

The Endocrine Society's 2018 Clinical Practice Guideline on male hypogonadism states: "We suggest confirming the diagnosis with a morning total testosterone measurement on at least two separate occasions before initiating treatment" [4]. A former bodybuilder presenting with fatigue, low libido, loss of lean mass, and depressed mood would meet the symptomatic criteria for evaluation, provided biochemical confirmation follows.

Distinguishing PASH From Primary and Secondary Hypogonadism

PASH is classified as secondary (hypogonadotropic) hypogonadism because the problem originates above the testes. LH and FSH are low or inappropriately normal despite low testosterone. This matters clinically because it changes treatment options. Men with secondary hypogonadism who want to preserve fertility may respond to clomiphene citrate 25 to 50 mg daily or human chorionic gonadotropin (hCG) 1,500 to 2,500 IU three times per week, both of which stimulate the pituitary-gonadal axis directly [4].

For men who have completed family planning or who do not respond to these approaches, standard TRT becomes the appropriate next step. Cutler, who has children and is in his 50s, has indicated that he is not concerned with fertility preservation, which aligns with the TRT pathway rather than the gonadotropin-stimulation pathway.

What TRT Actually Involves: Doses, Formulations, and Monitoring

Understanding what Cutler's described regimen might look like in clinical practice requires a brief tour of current TRT standards. The Endocrine Society guideline recommends restoring serum total testosterone to the mid-normal range for healthy young men, generally 400 to 700 ng/dL, as a treatment target [4].

Common Testosterone Formulations

Testosterone cypionate and testosterone enanthate are the two injectable esters most commonly prescribed in the United States. Both are administered intramuscularly or subcutaneously at doses of 100 to 200 mg every 7 to 14 days, or at lower doses (50 to 100 mg) on a weekly schedule to reduce peak-to-trough fluctuation [5]. The FDA has approved testosterone cypionate injection (Depo-Testosterone) for male hypogonadism at doses individualized to patient response [6].

Transdermal options include testosterone gel 1% (AndroGel, Testim) applied daily to the shoulders or upper arms at a starting dose of 50 mg/day, with titration to 100 mg/day based on morning serum levels drawn at least two weeks after initiation [6]. Patches (Androderm) deliver approximately 2 to 4 mg per day transdermally. Each formulation has different pharmacokinetic profiles, and a prescribing physician selects the format based on patient preference, cost, and the need to avoid secondary transfer to partners or children.

Required Monitoring

TRT is not a set-it-and-forget-it prescription. The Endocrine Society recommends measuring total testosterone 3 to 6 months after initiation, targeting the mid-normal range, along with hematocrit monitoring to detect erythrocytosis, a known dose-dependent side effect [4]. A 2013 meta-analysis in the Journal of Clinical Endocrinology and Metabolism (N = 1,214 across 19 trials) found that TRT increased hematocrit by a mean of 3.18 percentage points (P<0.001) versus placebo [7]. If hematocrit exceeds 54%, dose reduction or temporary discontinuation is standard.

Prostate-specific antigen (PSA) should be checked at baseline and at 3 to 6 months. In men over 40, digital rectal examination is recommended before starting therapy [4]. Bone density assessment with DEXA scanning is appropriate in hypogonadal men who have had prolonged low testosterone, since hypogonadism accelerates trabecular bone loss at a rate of approximately 1 to 3% per year [8].

Why Elite Bodybuilders Face Higher PASH Risk Than Recreational Lifters

The duration and magnitude of AAS use in professional bodybuilding differ categorically from recreational use. Competitive bodybuilders at the elite level may use stacked AAS cycles for 20 to 30 weeks per year across careers spanning one to three decades. That sustained suppression of GnRH and LH differs from a single 12-week recreational cycle, after which spontaneous HPG recovery is likely within 3 to 6 months [9].

Cascade Effects on the HPG Axis

Prolonged GnRH suppression leads to pituitary gonadotroph down-regulation. The Leydig cells of the testes, deprived of LH stimulation, reduce their number and their steroidogenic capacity. A 2019 study in the European Journal of Endocrinology found testicular volume in long-term AAS users was 34% lower than in non-user controls, and LH pulse amplitude was blunted even 14 months after cessation [10].

Cardiovascular and Metabolic Comorbidities

PASH does not exist in isolation. The same AAS exposure that suppresses the HPG axis also elevates LDL cholesterol, reduces HDL cholesterol, promotes left ventricular hypertrophy, and increases red blood cell mass. A 2017 study in Circulation (N = 140 current and former AAS users) found that former AAS users had a mean left ventricular ejection fraction of 52% versus 63% in non-user controls, and coronary atherosclerosis was more prevalent [11]. Any clinician managing TRT in a former elite bodybuilder needs to perform cardiac evaluation before prescribing, since exogenous testosterone raises hematocrit and, at supraphysiologic levels, can worsen existing cardiomyopathy.

Is TRT Safe Long-Term? What the Evidence Says

The safety profile of TRT at physiologic replacement doses is reasonably well-characterized in the general hypogonadal male population. The TRAVERSE trial (N = 5,204), published in the New England Journal of Medicine in 2023, was the first large cardiovascular safety trial for testosterone therapy in men with hypogonadism and pre-existing cardiovascular disease or high cardiovascular risk. TRAVERSE found that testosterone did not increase the rate of major adverse cardiovascular events (MACE) compared with placebo over a median follow-up of 33 months (hazard ratio 0.96, 95% CI 0.78 to 1.17) [12].

Concerns Specific to Former Bodybuilders

The TRAVERSE population was not former elite bodybuilders. Men with existing cardiomyopathy, polycythemia, or significant atherosclerotic burden from prior AAS use occupy a different risk tier than the general hypogonadal population studied in TRAVERSE. Clinicians prescribing TRT to former professional athletes should apply the monitoring standards at the higher end of guideline frequency: hematocrit and cardiovascular assessment every three months for the first year.

Fertility Considerations

Exogenous testosterone suppresses spermatogenesis. In men who have already fathered children and who are not planning additional pregnancies, this is typically not a concern. For those who are, hCG co-administration at 500 IU every other day has been shown to maintain intratesticular testosterone concentrations sufficient for spermatogenesis in men on concurrent testosterone therapy [13].

How Clinicians Evaluate Whether Someone Like Cutler Needs TRT

A clinician evaluating a 50-year-old former elite bodybuilder for TRT candidacy would follow a structured protocol based on the Endocrine Society 2018 guidelines and the American Urological Association's 2018 testosterone deficiency guideline.

Initial Assessment Checklist

The first step is symptom documentation using a validated tool such as the Androgen Deficiency in Aging Males (ADAM) questionnaire or the Aging Males' Symptoms (AMS) scale. Relevant symptoms include reduced libido, erectile dysfunction, fatigue, depressed mood, decreased muscle mass, and increased body fat. Two morning total testosterone measurements drawn before 10 a.m. On different days establish the biochemical baseline. A level below 300 ng/dL on both draws, accompanied by symptoms, meets the diagnostic threshold per the AUA guideline [4].

Secondary workup includes LH, FSH, prolactin, complete blood count, comprehensive metabolic panel, lipid panel, PSA, and thyroid function tests. For a former AAS user, adding estradiol (to detect aromatization issues) and SHBG (to estimate free testosterone) is standard practice [4].

Starting, Adjusting, and Stopping TRT

After confirming diagnosis, a physician typically starts testosterone cypionate at 100 mg per week subcutaneously, checks total testosterone at week 6 to 8, and adjusts dose to achieve a trough level of 400 to 550 ng/dL. If hematocrit climbs above 52%, the dose is reduced by 25 mg per week. If the patient does not experience symptom relief within 12 weeks at an adequate blood level, the diagnosis should be reconsidered and other contributors to fatigue and low libido explored [4].

Societal and Clinical Implications of Public Figures Discussing TRT

When a figure with Cutler's visibility discusses TRT openly, it has measurable downstream effects. Prescription volumes for testosterone rose 500% between 2000 and 2011 in the United States before leveling off following FDA safety communications in 2014 [14]. Public celebrity endorsement (implicit or explicit) is one driver researchers have cited for that increase.

The clinical community's concern is not that TRT gets discussed publicly. The concern is that men self-diagnose based on marketed symptoms of "low T" rather than on biochemical confirmation. The Endocrine Society's guideline language is clear: "We recommend against a general policy of offering testosterone therapy to all older men with low testosterone concentrations" [4]. Symptomatic confirmation plus two low-testosterone lab draws is the standard, not a questionnaire and a podcast ad.

Cutler's framing of TRT as physician-supervised medical maintenance actually aligns with responsible messaging. He has not advocated self-administration or black-market sourcing. That distinction separates his public statements from more problematic influencer content in the fitness space.